Abstract
CRM(197) is a carrier protein in certain conjugate vaccines. When multiple conjugate vaccines with the same carrier protein are administered simultaneously, reduced response to vaccines and/or antigens related to the carrier protein may occur. This study examined responses of infants who, in addition to diphtheria toxoid/tetanus toxoid/acellular pertussis vaccine (DTaP) received either diphtheria CRM(197)-based Haemophilus influenzae type b conjugate vaccine (HbOC) or HbOC and a diphtheria CRM(197)-based combination 9-valent pneumococcal conjugate vaccine/meningococcal group C conjugate vaccine. Administration of conjugate vaccines with CRM(197) carrier protein load >50 microg did not reduce response to CRM(197) conjugate vaccines or immunogenicity to immunologically cross-reactive diphtheria toxoid.
Publication types
-
Clinical Trial, Phase II
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Bacterial / blood
-
Bacterial Proteins / adverse effects*
-
Bacterial Proteins / immunology*
-
Diphtheria Toxoid / administration & dosage
-
Diphtheria-Tetanus-acellular Pertussis Vaccines / administration & dosage
-
Drug Interactions
-
Female
-
Haemophilus Vaccines / administration & dosage
-
Haemophilus Vaccines / adverse effects*
-
Haemophilus Vaccines / immunology*
-
Humans
-
Infant
-
Male
-
Meningococcal Vaccines / administration & dosage
Substances
-
Antibodies, Bacterial
-
Bacterial Proteins
-
Diphtheria Toxoid
-
Diphtheria-Tetanus-acellular Pertussis Vaccines
-
Haemophilus Vaccines
-
Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate
-
Meningococcal Vaccines
-
serogroup C meningococcal conjugate vaccine
-
HibTITER protein, Haemophilus influenzae